Effect of renal impairment on the pharmacokinetics of intravenous zanamivir.
- 1 January 1999
- journal article
- clinical trial
- Published by Springer Nature in Clinical Pharmacokinetics
- Vol. 36 (1), 13-19
- https://doi.org/10.2165/00003088-199936001-00002
Abstract
No abstract availableKeywords
This publication has 3 references indexed in Scilit:
- Pharmacokinetics of Zanamivir After Intravenous, Oral, Inhaled or Intranasal Administration to Healthy VolunteersClinical Pharmacokinetics, 1999
- 4-Guanidino-2,4-dideoxy-2,3-dehydro-N-acetylneuraminic acid is a highly effective inhibitor both of the sialidase (neuraminidase) and of growth of a wide range of influenza A and B viruses in vitroAntimicrobial Agents and Chemotherapy, 1993
- Rational design of potent sialidase-based inhibitors of influenza virus replicationNature, 1993